Cyrille Delpierre Unité Inserm 1027 «Epidémiologie et analyses en sante publique : risques, maladies chroniques et handicaps » Tel : 05 61 14 56 74
Research conducted by Cyrille Delpierre (INSERM Unit 1027 “Epidemiology and Public Health Analyses: Risks, Chronic Illness and Handicaps”) in collaboration with the French Cancer Registers Network assessed the proportion of patients potentially suffering from prostate cancer and currently over-diagnosed or over-treated in France. According to a study performed on 1840 patients, current over-treatment involves a considerable number of patients being treated for a cancerous tumour in what is known as Stage T1 (early tumours) and, to a lesser extent, patients suffering from tumours in stage T2 (more advanced tumours). These figures should be taken seriously because over-diagnosis or over-treatment can be associated with undesirable side effects such as impotence or incontinence.
This work has been published in the review Cancer Epidemiology.
The generalised use of the PSA test for prostate cancer treatment has led to earlier diagnosis of the condition. This development is an advance in itself, since the early stages are less serious and thus easier to cure. But not all prostate cancers are equally aggressive; like many diagnostic tests, the administration of PSA detects tumours more easily, including those that grow at a slower rate. Consequently, a considerable number of tumours diagnosed from a PSA test develop very slowly, thus exposing patients to the risks of over-diagnosis or over-treatment.
In the absence of markers that make it possible to identify tumours that are specifically aggressive, the main difficulty with prostate cancer diagnosis lies in assessing the benefits for the subject, taking account of the risks of over-diagnosis and over-treatment (which can vary between 30% and 50% according to the literature). It is therefore necessary to compare theoretical life expectancy, and thus to assess such cancers correctly. In practice, if the patient’s life expectancy exceeds 10 years, a period considered necessary for a cancer that has become clinically significant, the treatment is justified.
The purpose of the study conducted by Cyrille Delpierre was to assess the extent of the potential actual over-diagnosis and over-treatment for prostate cancer in France, by taking account of comorbidity rates liable to seriously affect theoretical life expectancy.
The sample consisted of 1840 patients diagnosed in 2001. The proportion of patients over-diagnosed and over-treated was assessed by comparing theoretical life expectancy (taking co-morbidity into account) to life expectancy for those living with the cancer.
It was possible to identify patients in a potential over-treatment situation, i.e. those whose theoretical life expectancy was less than their life expectancy when living with cancer, and among the latter group to discover whether they had actually been treated (either through surgery or through radiotherapy) and thus genuinely over-treated.
Two per cent of patients with stage T2 tumours had been over-treated, making 2% of patients who had had a prostate ablation and 4.9% who had received radiotherapy.
The presence of a co-morbidity considerably increases these proportions. Patients at stage T1 with more than two comorbidities were in a potential over-treatment situation in almost all cases and were actually over-treated in one third of all cases.
“One of the major limits in our study was working with patients diagnosed in 2001. The present situation is different. But the most recent data covering 2008 show inverse proportions of stages T1 and T2. T1 stages are now more frequent than T2. The proportion of minor stages during which a higher risk of over-treatment has been observed is now on the increase”, explains Cyrille Delpierre.
The main question for researchers around the debate as to the usefulness of PSA, and more generally surrounding all diagnoses, is there for not the test in itself but rather the choice of appropriate treatment.
Diagnosis is a process that starts with the offer of a PSA test, followed in the case of positive results by diagnostic examinations and suitable treatment if disease is detected. “In view of the over-treatment of prostate cancer that has been confirmed, treatment could be restricted, especially for patients with co-morbidities, to supervision that would make it possible to offer the treatment when it becomes appropriate”, proposes Cyrille Delpierre.
The difference observed between potential over-treatment and actual over-treatment is a sign that the risk of over-treatment has been taken into account by urologists, although it needs to be improved. This situation translates the difficulty in suggesting active monitoring and the difficulty of justifying a non-interventionist attitude for patients who are aware that they have cancer.
Over-diagnosis or over-treatment?
Over-diagnosis: the time between diagnosis and the emergence of clinical symptoms and/or death from cancer may be higher than life expectancy, since the cancer will not manifest itself or at least will not kill the person. This situation corresponds to the situation known as over-diagnosis.
Over-treatment: the decision to use an invasive treatment may be the origin of over-treatment when treating a cancer that has not been particularly intrusive during the life of an individual. It is therefore not always in the patient’s interest to be diagnosed and treated for a tumour that is unlikely to develop much, by using treatment that have undesirable side effects.
 Prostate cancer diagnosis is based on detecting a marker in the blood of a specific marker for prostate dysfunction (a specific antigen known as PSA)
Multidisciplinary teams from the AP-HP Paris public hospitals network (SAMU75 emergency response dispatch centers and Hôpital européen Georges-Pompidou), as well as from Inserm, the Université Paris-Descartes, and the Paris BSPP medical emergency service, compared, in the French capital, two strategies of extracorporeal ...
In an article in the New England Journal of Medicine published on April 19, the intermediate results of a clinical trial (HGB-205) led by Pr. Marina Cavazzana and her teams at the Necker-Enfants malades hospital AP-HP in collaboration with the Imagine Institute ...
Cyrille Delpierre a,b,*, Sébastien Lamy a,b, Michelle Kelly-Irving a,b, Florence Molinié c, Michel Velten d, Brigitte Tretarre e, Anne-Sophie Woronoff f, Antoine Buemi g, Bénédicte Lapôtre-Ledoux h, Simona Bara i, Anne-Valérie Guizard j, Marc Colonna k, Pascale Grosclaude a,b,l,m a Inserm, UMR1027, Toulouse F-31062, France b Université de Toulouse III, UMR1027, Toulouse F-31062, France c Registre des cancers de Loire-Atlantique-Vendée, 44093 Nantes, France d Registre des cancers du Bas-Rhin, Laboratoire d’épidémiologie et de santé publique – Faculté de médecine, 67085 Strasbourg, France e Registre des tumeurs de l’Hérault, 34298 Montpellier, France f Registre des tumeurs du Doubs et du Territoire de Belfort, CHRU 25030 Besançon, France g Registre des cancers du Haut-Rhin, 68051 Mulhouse, France h Registre des cancers de la Somme, 80054 Amiens, France i Registre des cancers de la Manche, 50102 Cherbourg, France j Registre des tumeurs du Calvados, 14076 Caen, France k Registre des cancers de l’Isère, 38043 Grenoble, France l Registre des cancers du Tarn, BP 37, 81001 Albi cedex, France m Institut Claudius-Regaud, 31052 Toulouse cedex, France Cancer Epidemiology